|
CUSIP No. G21515104
|
|
|
1.
|
Names of Reporting Persons.
Parfield International Ltd.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☒ (b) ◻
|
|
3.
|
SEC Use Only
|
|
4.
|
Source of Funds (See Instructions)
WC
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
|
6.
|
Citizenship or Place of Organization
British Virgin Islands
|
|
Number of Shares
Beneficially Owned by
Each Reporting Person
With
|
7.
|
Sole Voting Power
0 Ordinary Shares
|
|
8.
|
Shared Voting Power
2,137,696 Ordinary Shares
|
|
9.
|
Sole Dispositive Power
0 Ordinary Shares
|
|
10.
|
Shared Dispositive Power
2,137,696 Ordinary Shares
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,137,696 Ordinary Shares
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐
|
|
13.
|
Percent of Class Represented by Amount in Row (11)
5.5%(1)
|
|
14.
|
Type of Reporting Person (See Instructions)
CO
|
|
CUSIP No. G21515104
|
|
|
1.
|
Names of Reporting Persons.
Amplewood Resources Ltd.
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☒ (b) ◻
|
|
3.
|
SEC Use Only
|
|
4.
|
Source of Funds (See Instructions)
WC
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
|
6.
|
Citizenship or Place of Organization
British Virgin Islands
|
|
Number of Shares
Beneficially Owned by
Each Reporting Person
With
|
7.
|
Sole Voting Power
0 Ordinary Shares
|
|
8.
|
Shared Voting Power
0 Ordinary Shares
|
|
9.
|
Sole Dispositive Power
0 Ordinary Shares
|
|
10.
|
Shared Dispositive Power
0 Ordinary Shares
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
0 Ordinary Shares
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐
|
|
13.
|
Percent of Class Represented by Amount in Row (11)
0
|
|
14.
|
Type of Reporting Person (See Instructions)
CO
|
|
CUSIP No. G21515104
|
|
|
1.
|
Names of Reporting Persons.
Marc Chan
|
|
2.
|
Check the Appropriate Box if a Member of a Group (See Instructions).
(a) ☒ (b) ◻
|
|
3.
|
SEC Use Only
|
|
4.
|
Source of Funds (See Instructions)
AF
|
|
5.
|
Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
☐
|
|
6.
|
Citizenship or Place of Organization
Canada
|
|
Number of Shares
Beneficially Owned by
Each Reporting Person
With
|
7.
|
Sole Voting Power
0 Ordinary Shares
|
|
8.
|
Shared Voting Power
2,137,696 Ordinary Shares
|
|
9.
|
Sole Dispositive Power
0 Ordinary Shares
|
|
10.
|
Shared Dispositive Power
2,137,696 Ordinary Shares
|
|
11.
|
Aggregate Amount Beneficially Owned by Each Reporting Person
2,137,696 Ordinary Shares
|
|
12.
|
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
☐
|
|
13.
|
Percent of Class Represented by Amount in Row (11)
5.5%(1)
|
|
14.
|
Type of Reporting Person (See Instructions)
IN
|
|
(1)
|
Percentage calculated based on 38,788,096 Ordinary Shares issued and outstanding as of November 19, 2020 as provided by the
Issuer.
|
The following constitutes Amendment No. 8 to the Schedule 13D filed by the undersigned (“Amendment No. 7”). This Amendment No. 8 amends
Amendment Number 7 to Schedule 13D of the Reporting Persons dated January 4, 2021 to update certain information relating to the Reporting Persons as specifically set forth herein.
Pursuant to Rule 13d-2 promulgated under the Act, this Amendment No. 7 amends and supplements the Schedule 13D filed on September 27, 2019, as amended
by Amendment No. 1 filed on November 6, 2019, by Amendment No. 2 filed on March 20, 2020, by Amendment No. 3 filed on April 14, 2020, by Amendment No. 4 filed on September 17, 2020, by Amendment No. 5 filed on October 28, 2020, by Amendment No. 6
filed on November 20, 2020, and by Amendment No. 7 filed on January 4, 2021 (the “Schedule 13D”), with respect to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of China Biologic Products Holdings, Inc., a
company organized under the laws of the Cayman Islands (the “Issuer”).
Except as specifically provided herein, this Amendment No. 7 does not modify any of the information previously reported in the Schedule 13D. All
capitalized terms used herein which are not defined herein have the meanings given to such terms in the Schedule 13D.
Item 5. Interest in Securities of the Issuer.
As previously disclosed, all of the ordinary shares held by Parfield were subject to a pledge with a third party lender. On January 13, 2021, Parfield was informed by its lender that the pledge
had been released effective January 7, 2021 and accordingly, that no lien remained on such ordinary shares.
Item 6. Contracts, Arrangement, Understandings or Relationships with Respect to Securities of the Issuer.
Item 6 of the Schedule 13D is hereby amended and supplemented by adding the following at the end thereof:
The description of the removal of the lien on the ordinary shares held by Parfield is incorporated by reference to the disclosure in Item 5 above.
Item 7. Materials to be Filed as Exhibits.
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.